Literature DB >> 19361346

A treasure of pharmacogenomic insights into postprandial lipoproteinemia and therapeutic responses to fibrate therapy: lessons from GOLDN.

Robert S Rosenson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19361346     DOI： 10.1007/s11883-009-0026-6

Source DB:  PubMed          Journal:  Curr Atheroscler Rep        ISSN： 1523-3804            Impact factor:   5.113


× No keyword cloud information.
  15 in total

1.  Dietary intake of n-6 fatty acids modulates effect of apolipoprotein A5 gene on plasma fasting triglycerides, remnant lipoprotein concentrations, and lipoprotein particle size: the Framingham Heart Study.

Authors:  Chao-Qiang Lai; Dolores Corella; Serkalem Demissie; L Adrienne Cupples; Xian Adiconis; Yueping Zhu; Laurence D Parnell; Katherine L Tucker; Jose M Ordovas
Journal:  Circulation       Date:  2006-04-24       Impact factor: 29.690

2.  Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss.

Authors:  J P Bastard; C Jardel; E Bruckert; P Blondy; J Capeau; M Laville; H Vidal; B Hainque
Journal:  J Clin Endocrinol Metab       Date:  2000-09       Impact factor: 5.958

3.  Alimentary lipemia, postprandial triglyceride-rich lipoproteins, and common carotid intima-media thickness in healthy, middle-aged men.

Authors:  S Boquist; G Ruotolo; R Tang; J Björkegren; M G Bond; U de Faire; F Karpe; A Hamsten
Journal:  Circulation       Date:  1999-08-17       Impact factor: 29.690

4.  Endotoxin and cytokines increase hepatic sphingolipid biosynthesis and produce lipoproteins enriched in ceramides and sphingomyelin.

Authors:  R A Memon; W M Holleran; A H Moser; T Seki; Y Uchida; J Fuller; J K Shigenaga; C Grunfeld; K R Feingold
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-08       Impact factor: 8.311

5.  Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.

Authors:  Robert S Rosenson; David A Wolff; Anna L Huskin; Irene B Helenowski; Alfred W Rademaker
Journal:  Diabetes Care       Date:  2007-05-04       Impact factor: 19.112

6.  Mechanism of triglyceride lowering in mice expressing human apolipoprotein A5.

Authors:  Jamila Fruchart-Najib; Eric Baugé; Loredan-Stefan Niculescu; Tatiana Pham; Benoit Thomas; Corinne Rommens; Zouher Majd; Bryan Brewer; Len A Pennacchio; Jean-Charles Fruchart
Journal:  Biochem Biophys Res Commun       Date:  2004-06-25       Impact factor: 3.575

7.  Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women.

Authors:  I Stensvold; A Tverdal; P Urdal; S Graff-Iversen
Journal:  BMJ       Date:  1993-11-20

8.  ApoAV reduces plasma triglycerides by inhibiting very low density lipoprotein-triglyceride (VLDL-TG) production and stimulating lipoprotein lipase-mediated VLDL-TG hydrolysis.

Authors:  Frank G Schaap; Patrick C N Rensen; Peter J Voshol; Carlos Vrins; Hendrik N van der Vliet; Robert A F M Chamuleau; Louis M Havekes; Albert K Groen; Ko Willems van Dijk
Journal:  J Biol Chem       Date:  2004-04-16       Impact factor: 5.157

9.  Endocrinologic and metabolic effects of interleukin-6 in humans.

Authors:  J M Stouthard; J A Romijn; T Van der Poll; E Endert; S Klein; P J Bakker; C H Veenhof; H P Sauerwein
Journal:  Am J Physiol       Date:  1995-05

10.  Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome.

Authors:  Robert S Rosenson; Anna L Huskin; David A Wolff; Irene B Helenowski; Alfred W Rademaker
Journal:  Atherosclerosis       Date:  2008-02-01       Impact factor: 5.162
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.